RNLX vs. BNR, PSNL, ENZ, XGN, PMD, DMTK, BGLC, OPGN, FRES, and ACON
Should you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include Burning Rock Biotech (BNR), Personalis (PSNL), Enzo Biochem (ENZ), Exagen (XGN), Psychemedics (PMD), DermTech (DMTK), BioNexus Gene Lab (BGLC), OpGen (OPGN), Fresh2 Group (FRES), and Aclarion (ACON). These companies are all part of the "medical laboratories" industry.
Burning Rock Biotech (NASDAQ:BNR) and Renalytix (NASDAQ:RNLX) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.
Burning Rock Biotech has a net margin of -113.39% compared to Burning Rock Biotech's net margin of -1,687.80%. Renalytix's return on equity of -71.22% beat Burning Rock Biotech's return on equity.
Renalytix has lower revenue, but higher earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
Burning Rock Biotech has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 3.05, indicating that its share price is 205% more volatile than the S&P 500.
Renalytix received 3 more outperform votes than Burning Rock Biotech when rated by MarketBeat users. Likewise, 32.00% of users gave Renalytix an outperform vote while only 31.25% of users gave Burning Rock Biotech an outperform vote.
Renalytix has a consensus price target of $5.00, indicating a potential upside of 1,105.40%. Given Burning Rock Biotech's higher probable upside, analysts plainly believe Renalytix is more favorable than Burning Rock Biotech.
In the previous week, Burning Rock Biotech had 8 more articles in the media than Renalytix. MarketBeat recorded 10 mentions for Burning Rock Biotech and 2 mentions for Renalytix. Burning Rock Biotech's average media sentiment score of 1.19 beat Renalytix's score of 0.40 indicating that Renalytix is being referred to more favorably in the news media.
30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 9.9% of Renalytix shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by insiders. Comparatively, 18.3% of Renalytix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Renalytix beats Burning Rock Biotech on 10 of the 17 factors compared between the two stocks.
Get Renalytix News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renalytix Competitors List
Related Companies and Tools
